# Melatonin Stress Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/melatonin-stress-randomized-trial-evidence-review
Category: evidence-review
Summary: Melatonin Stress Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are syste
Last reviewed: 2026-08-18
Reviewed by: Migaku Evidence Review
# Melatonin Stress Randomized Trial: What the Evidence Says

## Quick Answer

Melatonin Stress Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials | systematic review | 1 | 2026-04-30 | 10.3390/jcm15093444 |
| Melatonin as a Pleiotropic Modulator of Mitochondrial Function and Cellular Signaling in Ischemic Brain Injury | preclinical study | 4 | 2026-06-15 | 10.3390/cells15121084 |

## What The Sources Report

- Despite a robust mechanistic basis, the existing clinical evidence regarding melatonin's cardiovascular efficacy is fragmented and inconsistent. [Ang Song Peng (2026); evidence level 1]
- We stratified data by distinct clinical settings, including perioperative cardiac surgery, acute myocardial infarction (AMI), and heart failure with reduced ejection fraction (HFrEF). [Ang Song Peng (2026); evidence level 1]
- Melatonin, an endogenous indoleamine traditionally associated with circadian regulation, has emerged as a pleiotropic regulator of cellular homeostasis. [Ortiz-Martínez Georgina (2026); evidence level 4]
- This review examines the cellular and molecular mechanisms underlying melatonin's neuroprotective effects and evaluates current preclinical and clinical evidence, highlighting key translational gaps and future directions for its investigation in acute ischemic stroke. [Ortiz-Martínez Georgina (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For melatonin stress randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Ang Song Peng (2026). Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials. DOI: 10.3390/jcm15093444. PMCID: PMC13164420. PMID: 42123177. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13164420/
- Ortiz-Martínez Georgina (2026). Melatonin as a Pleiotropic Modulator of Mitochondrial Function and Cellular Signaling in Ischemic Brain Injury. DOI: 10.3390/cells15121084. PMCID: PMC13296773. PMID: 42346111. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13296773/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.